Search

Your search keyword '"Hillman, David W"' showing total 259 results
Start Over Author "Hillman, David W"
259 results on '"Hillman, David W"'

2. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Author

Rediti, Mattia, Fernandez-Martinez, Aranzazu, Venet, David, Rothé, Françoise, Hoadley, Katherine A., Parker, Joel S., Singh, Baljit, Campbell, Jordan D., Ballman, Karla V., Hillman, David W., Winer, Eric P., El-Abed, Sarra, Piccart, Martine, Di Cosimo, Serena, Symmans, William Fraser, Krop, Ian E., Salgado, Roberto, Loi, Sherene, Pusztai, Lajos, Perou, Charles M., Carey, Lisa A., and Sotiriou, Christos

Published
2023
Full Text
View/download PDF

3. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer

Author

Carter, Jodi M., Chumsri, Saranya, Hinerfeld, Douglas A., Ma, Yaohua, Wang, Xue, Zahrieh, David, Hillman, David W., Tenner, Kathleen S., Kachergus, Jennifer M., Brauer, Heather Ann, Warren, Sarah E., Henderson, David, Shi, Ji, Liu, Yi, Joensuu, Heikki, Lindman, Henrik, Leon-Ferre, Roberto A., Boughey, Judy C., Liu, Minetta C., Ingle, James N., Kalari, Krishna R., Couch, Fergus J., Knutson, Keith L., Goetz, Matthew P., Perez, Edith A., and Thompson, E. Aubrey

Published
2023
Full Text
View/download PDF

4. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.

Author

Eastham, James A, Heller, Glenn, Halabi, Susan, Monk, J Paul, Beltran, Himisha, Gleave, Martin, Evans, Christopher P, Clinton, Steven K, Szmulewitz, Russell Z, Coleman, Jonathan, Hillman, David W, Watt, Colleen R, George, Saby, Sanda, Martin G, Hahn, Olwen M, Taplin, Mary-Ellen, Parsons, J Kellogg, Mohler, James L, Small, Eric J, and Morris, Michael J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prostate Cancer, Patient Safety, Urologic Diseases, Cancer, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Androgen Antagonists, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Disease Progression, Docetaxel, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Neoplasm Staging, Progression-Free Survival, Prostatectomy, Prostatic Neoplasms, Risk Assessment, Risk Factors, Time Factors, United States, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeRadical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progression-free survival (BPFS) over RP alone.Patients and methodsMen with clinically localized, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m2 body surface area every 3 weeks for 6 cycles) and RP. The primary end point was 3-year BPFS. Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 consecutive occasions that were at least 3 months apart. Secondary end points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS).ResultsIn total, 788 men were randomly assigned. Median follow-up time was 6.1 years. The overall rates of grade 3 and 4 adverse events during chemotherapy were 26% and 19%, respectively. No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, -0.01 to 0.11; P = .11). Neoadjuvant CHT was associated with improved overall BPFS (hazard ratio [HR], 0.69; 95% CI, 0.48 to 0.99), improved MFS (HR, 0.70; 95% CI, 0.51 to 0.95), and improved OS (HR, 0.61; 95% CI, 0.40 to 0.94) compared with RP alone.ConclusionThe primary study end point, 3-year BPFS, was not met. Although some improvement was seen in secondary end points, any potential benefit must be weighed against toxicity. Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time.

Published
2020

7. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Author

Hilbers, Florentine, El-Abed, Sarra, Balta, Vasiliki, Schurmans, Celine, Rosa, Daniela D., Saini, Kamal, Filho, Otto Metzger, McConnell, Robin, Paterson, Vicki, Campbell, Christine, McFadden, Eleanor, Paterson, Emma, Kassab, Garrick, Moreno-Aspitia, Alvaro, Holmes, Eileen M., Jackisch, Christian, de Azambuja, Evandro, Boyle, Frances, Hillman, David W., Korde, Larissa, Fumagalli, Debora, Izquierdo, Miguel A., McCullough, Ann E., Wolff, Antonio C., Pritchard, Kathleen I., Untch, Michael, Guillaume, Sébastien, Ewer, Michael S., Shao, Zhimin, Sim, Sung Hoon, Aziz, Zeba, Demetriou, Georgia, Mehta, Ajay O., Andersson, Michael, Toi, Masakazu, Lang, Istvan, Xu, Binghe, Smith, Ian E., Barrios, Carlos H., Baselga, Jose, Gelber, Richard D., and Piccart-Gebhart, Martine

Published
2021
Full Text
View/download PDF

8. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)

Author

Aggarwal, Rahul, primary, Heller, Glenn, additional, Hillman, David W., additional, Xiao, Han, additional, Picus, Joel, additional, Taplin, Mary-Ellen, additional, Dorff, Tanya, additional, Appleman, Leonard, additional, Weckstein, Douglas, additional, Patnaik, Akash, additional, Bryce, Alan, additional, Shevrin, Daniel, additional, Mohler, James, additional, Anderson, Daniel, additional, Rao, Arpit, additional, Tagawa, Scott, additional, Tan, Alan, additional, Halabi, Susan, additional, Dooley, Katharine, additional, O'Brien, Patrick, additional, Chen, Ronald, additional, Ryan, Charles J., additional, Eggener, Scott E., additional, Morris, Michael J., additional, Aggarwal, Rahul, additional, Kim, Charles, additional, Whang, Young, additional, Dakhil, Shaker, additional, Smith, Raymond, additional, Gartrell, Benjamin, additional, Fagbemi, Seth, additional, Mowat, Rex, additional, Farber, Charles, additional, Hashemi, Neda, additional, Humeniuk, Michael, additional, Ryan, Charles, additional, Ellerton, John, additional, Olsen, Mark, additional, Wang, Jennifer, additional, Karina Pascual, Sheila, additional, Michael Randall, James, additional, King, David, additional, Kilari, Deepak, additional, Monk, Paul, additional, Bitting, Rhonda, additional, Eugenio Najera, Jose, additional, Rowland, Kendrith, additional, Hauke, Ralph, additional, Shehadeh, Nasfat, additional, Curti, Brendan, additional, Gupta, Gopal, additional, Collins, Timothy, additional, Beer, Tomasz, additional, Tate, David, additional, Sheh, Bryant, additional, Basnet, Alina, additional, Conway, James, additional, Gross, Howard, additional, and Goodman, Michael, additional

Published
2024
Full Text
View/download PDF

9. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer

Author

Polley, Mei-Yin C., Leon-Ferre, Roberto A., Leung, Samuel, Cheng, Angela, Gao, Dongxia, Sinnwell, Jason, Liu, Heshan, Hillman, David W., Eyman-Casey, Abraham, Gilbert, Judith A., Negron, Vivian, Boughey, Judy C., Liu, Minetta C., Ingle, James N., Kalari, Krishna, Couch, Fergus, Carter, Jodi M., Visscher, Daniel W., Nielsen, Torsten O., and Goetz, Matthew P.

Published
2021
Full Text
View/download PDF

10. Benign Breast Disease and the Risk of Breast Cancer

Author

Hartmann, Lynn C, Sellers, Thomas A, Frost, Marlene H, Lingle, Wilma L, Degnim, Amy C, Ghosh, Karthik, Vierkant, Robert A, Maloney, Shaun D, Pankratz, V Shane, Hillman, David W, Suman, Vera J, Johnson, Jo, Blake, Cassann, Tlsty, Thea, Vachon, Celine M, Melton, L Joseph, and Visscher, Daniel W

Subjects
Patient Safety, Clinical Research, Cancer, Breast Cancer, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
Published
2016

12. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients

Author

Norton, Nadine, Youssef, Bahaaeldin, Hillman, David W., Nassar, Aziza, Geiger, Xochiquetzal J., Necela, Brian M., Liu, Heshan, Ruddy, Kathryn J., Polley, Mei-Yin C., Ingle, James N., Couch, Fergus J., Perez, Edith A., Liu, Minetta C., Carter, Jodi M., Leon-Ferre, Roberto A., Boughey, Judy C., Somers, Elizabeth B., Kalari, Krishna R., Visscher, Daniel W., Goetz, Matthew P., and Knutson, Keith L.

Published
2020
Full Text
View/download PDF

13. Benign Breast Disease and the Risk of Breast Cancer

Author

Hartmann, Lynn C, Sellers, Thomas A, Frost, Marlene H, Lingle, Wilma L, Degnim, Amy C, Ghosh, Karthik, Vierkant, Robert A, Maloney, Shaun D, Pankratz, V Shane, Hillman, David W, Suman, Vera J, Johnson, Jo, Blake, Cassann, Tlsty, Thea, Vachon, Celine M, Melton, L Joseph, and Visscher, Daniel W

Subjects
Cancer, Prevention, Clinical Research, Breast Cancer, Adult, Age of Onset, Aged, Breast, Breast Diseases, Breast Neoplasms, Cohort Studies, Female, Fibrocystic Breast Disease, Humans, Hyperplasia, Middle Aged, Proportional Hazards Models, Risk, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundBenign breast disease is an important risk factor for breast cancer. We studied a large group of women with benign breast disease to obtain reliable estimates of this risk.MethodsWe identified all women who received a diagnosis of benign breast disease at the Mayo Clinic between 1967 and 1991. Breast-cancer events were obtained from medical records and questionnaires. To estimate relative risks, we compared the number of observed breast cancers with the number expected on the basis of the rates of breast cancer in the Iowa Surveillance, Epidemiology, and End Results registry.ResultsWe followed 9087 women for a median of 15 years. The histologic findings were nonproliferative lesions in 67 percent of women, proliferative lesions without atypia in 30 percent, and atypical hyperplasia in 4 percent. To date, 707 breast cancers have developed. The relative risk of breast cancer for the cohort was 1.56 (95 percent confidence interval, 1.45 to 1.68), and this increased risk persisted for at least 25 years after biopsy. The relative risk associated with atypia was 4.24 (95 percent confidence interval, 3.26 to 5.41), as compared with a relative risk of 1.88 (95 percent confidence interval, 1.66 to 2.12) for proliferative changes without atypia and of 1.27 (95 percent confidence interval, 1.15 to 1.41) for nonproliferative lesions. The strength of the family history of breast cancer, available for 4808 women, was a risk factor that was independent of histologic findings. No increased risk was found among women with no family history and nonproliferative findings. In the first 10 years after the initial biopsy, an excess of cancers occurred in the same breast, especially in women with atypia.ConclusionsRisk factors for breast cancer after the diagnosis of benign breast disease include the histologic classification of a benign breast lesion and a family history of breast cancer.

Published
2005

16. Supplementary Figure from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment

Author

Sicotte, Hugues, primary, Kalari, Krishna R., primary, Qin, Sisi, primary, Dehm, Scott M., primary, Bhargava, Vipul, primary, Gormley, Michael, primary, Tan, Winston, primary, Sinnwell, Jason P., primary, Hillman, David W., primary, Li, Ying, primary, Vedell, Peter T., primary, Carlson, Rachel E., primary, Bryce, Alan H., primary, Jimenez, Raphael E., primary, Weinshilboum, Richard M., primary, Kohli, Manish, primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

17. Data from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment

Author

Sicotte, Hugues, primary, Kalari, Krishna R., primary, Qin, Sisi, primary, Dehm, Scott M., primary, Bhargava, Vipul, primary, Gormley, Michael, primary, Tan, Winston, primary, Sinnwell, Jason P., primary, Hillman, David W., primary, Li, Ying, primary, Vedell, Peter T., primary, Carlson, Rachel E., primary, Bryce, Alan H., primary, Jimenez, Raphael E., primary, Weinshilboum, Richard M., primary, Kohli, Manish, primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data from Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment

Author

Sicotte, Hugues, primary, Kalari, Krishna R., primary, Qin, Sisi, primary, Dehm, Scott M., primary, Bhargava, Vipul, primary, Gormley, Michael, primary, Tan, Winston, primary, Sinnwell, Jason P., primary, Hillman, David W., primary, Li, Ying, primary, Vedell, Peter T., primary, Carlson, Rachel E., primary, Bryce, Alan H., primary, Jimenez, Raphael E., primary, Weinshilboum, Richard M., primary, Kohli, Manish, primary, and Wang, Liewei, primary

Published
2023
Full Text
View/download PDF

19. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer

Author

Choo, Richard, primary, Hillman, David W., additional, Mitchell, Cecilia, additional, Daniels, Thomas, additional, Vargas, Carlos, additional, Rwigema, Jean Claude, additional, Corbin, Kimberly, additional, Keole, Sameer, additional, Vora, Sujay, additional, Merrell, Kenneth, additional, Stish, Bradley, additional, Pisansky, Thomas, additional, Davis, Brian J., additional, Amundson, Adam, additional, and Wong, William, additional

Published
2023
Full Text
View/download PDF

20. Supplementary Methods, Supplementary References, Supplementary Tables 1-3, Supplementary Figures 1-4 from Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance

Author

Kohli, Manish, primary, Ho, Yeung, primary, Hillman, David W., primary, Van Etten, Jamie L., primary, Henzler, Christine, primary, Yang, Rendong, primary, Sperger, Jamie M., primary, Li, Yingming, primary, Tseng, Elizabeth, primary, Hon, Ting, primary, Clark, Tyson, primary, Tan, Winston, primary, Carlson, Rachel E., primary, Wang, Liguo, primary, Sicotte, Hugues, primary, Thai, Ho, primary, Jimenez, Rafael, primary, Huang, Haojie, primary, Vedell, Peter T., primary, Eckloff, Bruce W., primary, Quevedo, Jorge F., primary, Pitot, Henry C., primary, Costello, Brian A., primary, Jen, Jin, primary, Wieben, Eric D., primary, Silverstein, Kevin A.T., primary, Lang, Joshua M., primary, Wang, Liewei, primary, and Dehm, Scott M., primary

Published
2023
Full Text
View/download PDF

21. Association of whole blood mRNA expression and overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC).

Author

Lewis, Akeem Ronell, primary, Sosa, Carlos, additional, Bobek, Olivia, additional, Hillman, David W., additional, Costello, Brian Addis, additional, Quevedo, Fernando, additional, Pagliaro, Lance C., additional, Weinshilboum, Richard M., additional, Cairns, Junmei, additional, Wang, Leiwei, additional, Kalari, Krishna Rani, additional, Kohli, Manish, additional, Tan, Winston, additional, and Giridhar, Karthik, additional

Published
2023
Full Text
View/download PDF

22. Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).

Author

Aggarwal, Rahul Raj, primary, Heller, Glenn, additional, Hillman, David W., additional, Xiao, Han, additional, Picus, Joel, additional, Taplin, Mary-Ellen, additional, Dorff, Tanya B., additional, Appleman, Leonard Joseph, additional, Weckstein, Douglas Jay, additional, Patnaik, Akash, additional, Bryce, Alan Haruo, additional, Shevrin, Daniel H., additional, Mohler, James, additional, Anderson, Daniel M., additional, Rao, Arpit, additional, Tagawa, Scott T., additional, Tan, Alan, additional, Eggener, Scott E., additional, Ryan, Charles J., additional, and Morris, Michael J., additional

Published
2023
Full Text
View/download PDF

23. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer

Author

Leon-Ferre, Roberto A., Polley, Mei-Yin, Liu, Heshan, Gilbert, Judith A., Cafourek, Victoria, Hillman, David W., Elkhanany, Ahmed, Akinhanmi, Margaret, Lilyquist, Jenna, Thomas, Abigail, Negron, Vivian, Boughey, Judy C., Liu, Minetta C., Ingle, James N., Kalari, Krishna R., Couch, Fergus J., Visscher, Daniel W., and Goetz, Matthew P.

Published
2017
Full Text
View/download PDF

24. Molecular profile changes in castrate resistant prostate cancer patients pre and post-abiraterone/prednisone treatment

Author

Sicotte, Hugues, Kalari, Krishna R., Qin, Sisi, Dehm, Scott M., Bhargava, Vipul, Gormley, Michael, Tan, Winston, Sinnwell, Jason P., Hillman, David W., Li, Ying, Vedell, Peter T., Carlson, Rachel E., Bryce, Alan H., Jimenez, Raphael E, Weinshilboum, Richard M., Kohli, Manish, and Wang, Liewei

Subjects
Male, Prostatic Neoplasms, Castration-Resistant, Antineoplastic Combined Chemotherapy Protocols, Abiraterone Acetate, Humans, Prednisone, Article, Aurora Kinase A
Abstract

We identified resistance mechanisms to abiraterone acetate/prednisone (AA/P) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PROMOTE (Prostate Cancer Medically Optimized Genome-Enhanced Therapy) study. We analyzed whole-exome sequencing (WES) and RNA-seq data from 83 patients with metastatic biopsies pre (V1) and after 12 weeks of AA/P treatment (V2). Resistance was determined by time to treatment change (TTTC). At V2, 18 and 11 out of 58 patients had either short (median 3.6 months; range 1.4–4.5) or long- (median 29 months; range 23.5–41.7) term responses, respectively. Non-responders had low expression of TGFBR3 and increased activation of the Wnt pathway, cell cycle, upregulation of AR variants, both pre and post-treatment, with further deletion of AR inhibitor CDK11B post-treatment. Deletion of androgen processing genes, HSD17B11, CYP19A1 were observed in non-responders post-treatment. Genes involved in cell cycle, DNA repair, Wnt-signaling, and Aurora kinase pathways were differentially expressed between the responder and non-responder at V2. Activation of Wnt signaling in non-responder and deactivation of MYC or its target genes in responders was detected via Somatic Copy Number (SCN) loss, somatic mutations, and transcriptomics. Upregulation of genes in the AURKA pathway are consistent with the activation of MYC regulated genes in non-responders. Several genes in the AKT1 axis had increased mutation rate in non-responders. We also found evidence of resistance via PD1 overexpression in responders. Implications: Finally, we identified candidates drugs to reverse AA/P resistance : topoisomerase inhibitors and drugs targeting the cell cycle via the MYC/AURKA/AURKB/TOP2A and/or PI3K/AKT1/MTOR pathways.

Published
2022

25. Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment

Author

Sicotte, Hugues, primary, Kalari, Krishna R., additional, Qin, Sisi, additional, Dehm, Scott M., additional, Bhargava, Vipul, additional, Gormley, Michael, additional, Tan, Winston, additional, Sinnwell, Jason P., additional, Hillman, David W., additional, Li, Ying, additional, Vedell, Peter T., additional, Carlson, Rachel E., additional, Bryce, Alan H., additional, Jimenez, Raphael E., additional, Weinshilboum, Richard M., additional, Kohli, Manish, additional, and Wang, Liewei, additional

Published
2022
Full Text
View/download PDF

26. A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient‐reported quality of life

Author

Wong, William W., primary, Hillman, David W., additional, Daniels, Thomas B., additional, Vargas, Carlos E., additional, Rwigema, Jean Claude, additional, Corbin, Kimberly S., additional, Keole, Sameer R., additional, Merrell, Kenneth W., additional, Stish, Bradley J., additional, Pisansky, Thomas M., additional, Davis, Brian J., additional, Mitchell, Cecilia M., additional, and Choo, Richard, additional

Published
2022
Full Text
View/download PDF

27. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).

Author

Morris, Michael J., Heller, Glenn, Hillman, David W., Bobek, Olivia, Ryan, Charles, Antonarakis, Emmanuel S., Bryce, Alan H., Hahn, Olwen, Beltran, Himisha, Armstrong, Andrew J., Schwartz, Lawrence, Lewis, Lionel D., Beumer, Jan H., Langevin, Brooke, McGary, Eric C., Mehan, Paul T., Goldkorn, Amir, Roth, Bruce J., Xiao, Han, and Watt, Colleen

Published
2023
Full Text
View/download PDF

29. Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residual disease post-neoadjuvant chemotherapy.

Author

Chumsri, Saranya, primary, Norton, Nadine, additional, Bruggeman, Sarah, additional, Hillman, David W., additional, Ernst, Brenda, additional, Ruddy, Kathryn Jean, additional, Northfelt, Donald W., additional, Advani, Pooja Prem, additional, Sideras, Kostandinos, additional, Moreno-Aspitia, Alvaro, additional, Goetz, Matthew P., additional, and Knutson, Keith L., additional

Published
2022
Full Text
View/download PDF

30. Abstract P1-04-01: Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC)

Author

Leon-Ferre, Roberto A, primary, Carter, Jodi M., additional, Zahrieh, David M., additional, Hillman, David W., additional, Chumsri, Saranya, additional, Ma, Yaohua, additional, Kachergus, Jennifer M., additional, Wang, Xue, additional, Boughey, Judy C., additional, Liu, Minetta C., additional, Ingle, James N., additional, Kalari, Krishna R., additional, Villasboas Bisneto, Jose C., additional, Couch, Fergus J., additional, Thompson, E. Aubrey, additional, and Goetz, Matthew P., additional

Published
2022
Full Text
View/download PDF

32. Long-term outcomes of patients with node-negative (N0), triple-negative breast cancer (TNBC) who did not receive adjuvant chemotherapy according to stromal TILs (sTILs).

Author

Leon-Ferre, Roberto Antonio, primary, Carter, Jodi M, additional, Hillman, David W., additional, Tenner, Kathleen S., additional, Zahrieh, David, additional, Liu, Minetta C., additional, Ingle, James N., additional, Kalari, Krishna R., additional, Visscher, Daniel W., additional, Boughey, Judy Caroline, additional, Couch, Fergus, additional, and Goetz, Matthew P., additional

Published
2021
Full Text
View/download PDF

33. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Author

Moreno-Aspitia, Alvaro, primary, Holmes, Eileen M., additional, Jackisch, Christian, additional, de Azambuja, Evandro, additional, Boyle, Frances, additional, Hillman, David W., additional, Korde, Larissa, additional, Fumagalli, Debora, additional, Izquierdo, Miguel A., additional, McCullough, Ann E., additional, Wolff, Antonio C., additional, Pritchard, Kathleen I., additional, Untch, Michael, additional, Guillaume, Sébastien, additional, Ewer, Michael S., additional, Shao, Zhimin, additional, Sim, Sung Hoon, additional, Aziz, Zeba, additional, Demetriou, Georgia, additional, Mehta, Ajay O., additional, Andersson, Michael, additional, Toi, Masakazu, additional, Lang, Istvan, additional, Xu, Binghe, additional, Smith, Ian E., additional, Barrios, Carlos H., additional, Baselga, Jose, additional, Gelber, Richard D., additional, Piccart-Gebhart, Martine, additional, Hilbers, Florentine, additional, El-Abed, Sarra, additional, Balta, Vasiliki, additional, Schurmans, Celine, additional, Rosa, Daniela D., additional, Saini, Kamal, additional, Filho, Otto Metzger, additional, McConnell, Robin, additional, Paterson, Vicki, additional, Campbell, Christine, additional, McFadden, Eleanor, additional, Paterson, Emma, additional, and Kassab, Garrick, additional

Published
2021
Full Text
View/download PDF

35. Abstract PS16-01: Intra-epithelial tumor immune landscapes are associated with clinical outcomes in early-stage triple-negative breast cancer

Author

Carter, Jodi M, primary, Chumsri, Saranya, additional, Hillman, David W, additional, Zahrieh, David M, additional, Ma, Yaohua, additional, Wang, Xue, additional, Kachergus, Jennifer M, additional, Boughey, Judy C, additional, Liu, Minetta C, additional, Kalari, Krishna R, additional, Villasboas, JC, additional, Ferre, Roberto A Leon, additional, Couch, Fergus J, additional, Goetz, Matthew P, additional, and Thompson, E. Aubrey, additional

Published
2021
Full Text
View/download PDF

36. Abstract PS6-02: Spatially defined immune-related proteins and outcome in triple negative breast cancer in the FinXX trial and Mayo Clinic cohort

Author

Chumsri, Saranya, primary, Carter, Jodi M., additional, Ma, Yaohua, additional, Hinerfeld, Douglas, additional, Brauer, Heather Ann, additional, Warren, Sarah, additional, Nielsen, Torsten O., additional, Asleh, Karama, additional, Joensuu, Heikki, additional, Perez, Edith A., additional, Leon-Ferre, Roberto A., additional, Hillman, David W., additional, Boughey, Judy C., additional, Liu, Minetta C., additional, Ingle, James N., additional, Kalari, Krishna R., additional, Couch, Fergus J., additional, Knutson, Keith L., additional, Goetz, Matthew P., additional, and Thompson, E. A., additional

Published
2021
Full Text
View/download PDF

37. Benign breast disease and the risk of breast cancer

Author

Blake, Cassann, Sellers, Thomas A., Frost, Marlene H., Lingle, Wilma L., Degnim, Amy C., Ghosh, Karthik, Vierkant, RObert A., Maloney, Shaun D., Pantratz, V.Shane, Hillman, David W., Suman, Vera J., Hohnson, Jo, Melton, Joseph L., III, and Visscher, Daniel W.

Subjects
Breast cancer -- Risk factors, Women -- Health aspects
Abstract

A large group of women with benign breast disease are studied to obtain reliable estimates of the risk of breast cancer. The risk factors for breast cancer include the histologic classification of a benign lesion and a family history of breast cancer.

Published
2005

38. Soluble Human Epidermal Growth Factor Receptor 2 (HER2) Levels in Patients With HER2-Positive Breast Cancer Receiving Chemotherapy With or Without Trastuzumab: Results From North Central Cancer Treatment Group Adjuvant Trial N9831

Author

Moreno-Aspitia, Alvaro, Hillman, David W., Dyar, Stephen H., Tenner, Kathleen S., Gralow, Julie, Kaufman, Peter A., Davidson, Nancy E., Lafky, Jacqueline M., Reinholz, Monica M., Lingle, Wilma L., Kutteh, Leila A., Carney, Walter P., Dueck, Amylou C., and Perez, Edith A.

Published
2013
Full Text
View/download PDF

41. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

Author

Fernandez-Martinez, Aranzazu, primary, Krop, Ian E., additional, Hillman, David W., additional, Polley, Mei-Yin, additional, Parker, Joel S., additional, Huebner, Lucas, additional, Hoadley, Katherine A., additional, Shepherd, Jonathan, additional, Tolaney, Sara, additional, Henry, N. Lynn, additional, Dang, Chau, additional, Harris, Lyndsay, additional, Berry, Donald, additional, Hahn, Olwen, additional, Hudis, Clifford, additional, Winer, Eric, additional, Partridge, Ann, additional, Perou, Charles M., additional, and Carey, Lisa A., additional

Published
2020
Full Text
View/download PDF

42. Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.

Author

Chumsri, Saranya, primary, Carter, Jodi M, additional, Ma, Yaohua, additional, Hinerfeld, Douglas, additional, Brauer, Heather Ann, additional, Warren, Sarah, additional, Nielsen, Torsten O, additional, Asleh, Karama, additional, Joensuu, Heikki, additional, Perez, Edith A., additional, Leon-Ferre, Roberto Antonio, additional, Hillman, David W., additional, Boughey, Judy Caroline, additional, Liu, Minetta C., additional, Ingle, James N., additional, Kalari, Krishna R., additional, Couch, Fergus, additional, Knutson, Keith L., additional, Goetz, Matthew P., additional, and Thompson, E Aubrey, additional

Published
2020
Full Text
View/download PDF

43. Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).

Author

Liu, Minetta C., primary, Hillman, David W., additional, Frith, Ashley Elizabeth, additional, Lyss, Alan P., additional, Weckstein, Douglas Jay, additional, Moreno-Aspitia, Alvaro, additional, Le-Lindqwister, Nguyet, additional, Isaacs, Claudine, additional, Wender, Donald B., additional, Lewis, DeQuincy Andrew, additional, Cole, John T., additional, Jaslowski, Anthony John, additional, Rowland, Kendrith M., additional, Openshaw, Thomas H., additional, Friday, Bret Edward Buckley, additional, Fleming, Gini F., additional, Asmus, Erik, additional, Rogak, Lauren J., additional, Basch, Ethan M., additional, and Dueck, Amylou C., additional

Published
2020
Full Text
View/download PDF

44. Phase II efficacy trial of pazopanib in nonclear cell metastatic renal cell cancer (mRCC): PINCR.

Author

Costello, Brian Addis, primary, Ho, Thai Huu, additional, Perez Burbano, Gabriela, additional, Hillman, David W., additional, Quevedo, Fernando, additional, Pitot, Henry C., additional, Pagliaro, Lance C., additional, Bryce, Alan Haruo, additional, Tan, Winston, additional, Joseph, Richard Wayne, additional, Leibovich, Bradley C., additional, Castle, Erik P., additional, Dronca, Roxana Stefania, additional, and Kohli, Manish, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results